Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.
暂无分享,去创建一个
Lust | R. Fonseca | D. Dingli | A. Dispenzieri | R. Kyle | Shaji K. Kumar | S. Rajkumar | S. Russell | M. Gertz | J. Lust | M. Lacy | R. Ketterling | S. Hayman | F. Buadi | S. Zeldenrust | A. Greenberg | S. Russell | R. Knudson | L. Bergsagel | R. Kyle | R. Kyle | Lacy | Q. Martha | A. Ryan | Knudson | A. John
[1] Hajime Uno,et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. , 2011, Blood.
[2] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Fonseca,et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. , 2010, Mayo Clinic proceedings.
[4] Robert A Kyle,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.
[5] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[6] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[7] R. Fonseca,et al. Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? , 2008, Leukemia.
[8] John D. Shaughnessy,et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. , 2008, Blood.
[9] B. Grosbois,et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials , 2007, Leukemia.
[10] B. Barlogie,et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics , 2007, British journal of haematology.
[11] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[12] Rafael Fonseca,et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.
[13] R. Fonseca,et al. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma , 2006, Genes, chromosomes & cancer.
[14] G. Morgan,et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.
[15] G. Ahmann,et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.
[16] G. Ahmann,et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.
[17] G. Ahmann,et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.
[18] F. Magrangeas,et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma , 2005, Leukemia.
[19] D. Reece,et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. , 2004, Blood.
[20] H. Einsele,et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.
[21] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[22] R. Bataille,et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.
[23] M. Fiegl,et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. , 1998, Blood.
[24] J. Miguel,et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. , 1998, Blood.
[25] M. Ng,et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.
[26] U. Jäger,et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. , 1995, Cancer research.
[27] W. O'Fallon,et al. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma , 1993 .
[28] R. Bataille,et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report , 2004 .
[29] Lust,et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.